Remedy Health Media's Mike Collins discusses ways pharma and healthcare companies have shifted their strategies in the years after the success of blockbuster drugs.
Croom Lawrence and Kent Groves of Merkle Health explain being human.
Recently, Forbes ran an article from Wild Pixel Media founder and CEO Carlos Machicao lamenting the fact that healthcare advertising is boring.
For some, the term machine learning may conjure up images of virtual assistants or automated tools.
As researchers and analysts, we interact with a wide array of market research pros in the health and wellness space.
A study by Cohn & Wolfe cited that 63% of consumers would choose a company they believe to be authentic over its competitors.
Our understanding of how cancer develops and thrives has grown.
Only 2.6% of board members in Standard & Poor's 1,500 firms have marketing experience.
Every agency in the biz claims to have a "unique" culture and one that fuels a great deal of its success.
The e-giant is reportedly doing everything from starting secret labs and online pharmacies to redefining the hospital experience and democratizing health data.
If scientific storytelling alone can impact health outcomes, then how can we apply that knowledge in practice?
More than other patient groups, they want a deeper, ongoing relationship with caregivers.
Healthcare is one industry that hangs in this delicate balance, in large part due to the fact that it necessitates a blend of science and empathy.
At the very least, pharma marketers need to make sure they know the difference between search engine marketing and search engine optimization.
Few questions give healthcare marketers more heart palpitations than this one: "How do you know it will work?"
The presumption is Dr. A saw ad B, clicked on it, went to the site and within C time, prescribed product D.
The 2009 documentary offers a wealth of detail. Which is why it makes no sense that Genentech doesn't want you to see the damn thing.
Pharma and biotech can bolster their value through the analytics efforts of their health economics and outcomes teams.
There's a reason pharma lags on the programmatic adoption curve: It's a heavily regulated industry, and there are concerns around privacy.
Today's ambitious marketers and media people want to be the ones to not only figure out how to work within the regulations but also to create better work than ever before.
We should make off-label research publicly available in a non-promotional format to both healthcare professionals and patients.
Despite political rifts that have blocked progress on so many other fronts, Congress has managed to lay the groundwork for clear steps forward in mental health.
It's becoming less and less likely that an in-person physician/sales rep interaction will take place at the healthcare provider's office.
I was successful because I learned how business gets done, and that often meant learning to act like one of the guys.
The power of hackathons is now magnified because of the power of the internet and social media, giving both patients and healthcare professionals a global platform for their voices.
Imagine if the agencies pitching us mocha lattes faced these consumer beliefs: The latte will hurt when I drink it. The latte might leave me with a rash or cause me to vomit.
It's time for meetings that revolve around rosé on the Carlton Terrace. It's also time for the professional creative inferiority complex to pop up for people who make pharma ads.
Maybe it's time for pharma and healthcare marketers to put all the "patient-centric" talk on the shelf — not the actual paying-attention-to-patients part of it, but the trumpeting of it as the most noble of life-science virtues.
Time is everything, yet no one has enough of it. But especially in healthcare marketing, time and timing win customers.
Exactly how does the erosion of public trust in the goodwill of the pharma industry impact the work being done to raise awareness and also market medicines? It's hard to tell, so far.
One conversation with a real patient—followed by many more conversations with more patients—helped me see how important our work can be in the eyes of patients.
Curating personal relationships is one of the most valuable functions medical marketers can provide. The best way is through face-to-face interaction.
The traditional line of attack is genuine and requires little in the way of spin—yet still, every time a Turing rears its head, it gets blown back in small and indigestible pieces.
The kits aren't likely to enhance American Girl's bottom line in any significant way, yet the flood of press coverage painted the company as compassionate in a way that few such organizations are.
Many of the characters we are now meeting do not appear to be directed at a patient insight or purposefully used to de-stigmatize a disease.
Amazon's Echo—a voice-activated personal assistant like Siri—has been available to the public for a year now.
How did the WWE keep me interested for the last 20 years?
There is another revolution that is waiting to happen: one in how we get orphan drugs to patients who need them and help them stay on track with treatment.
Big pharma has used multichannel marketing for years and medical-device makers have long utilized inside sales, but neither has systematically cracked the code on developing effective and fully integrated sales and marketing programs.
Multiple marketing channels offer an effective way to ensure that meaningful relationships can be developed with prospects and when done right can increase revenue by more than 10% while reducing costs by 25%, if not both
Well-designed studies can deliver actionable information that optimizes customer engagement
Storytellers can both build meaningful story lines out of trend lines and construct rationales from ratios
Sales reps, supported by rich customer data, will become relationship managers
Safety information is knowledge. And, in the pursuit of public health, knowledge is power